Articles

Poll

Podcasts

Slideshows

Videos

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.


VIASKIN Peanut Patch Shows Strong Phase 3 VITESSE Results, With David Fleischer, MD

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

VIASKIN Peanut Patch Shows Strong Desensitization in Phase 3 Trial, With David Fleischer, MD

TreEAT: Clinical Implications, Screening Practices, and Next Steps, With Vicki McWilliam, MND, PhD

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.

Dupilumab Improves Desensitization Outcomes in OIT, With Sayantani Sindher, MD

Wood discussed the potential of BTK inhibition for peanut allergy and beyond.

Remibrutinib Enables Peanut Tolerance in as Little as 1 Week, With Robert Wood, MD

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

HCPLive Five at AAAAI 2026

Wood discussed factors that go into shared decision making for multi-food allergy.

Omalizumab or Oral Immunotherapy for Food Allergy, With Robert Wood, MD

McWilliam discussed findings from the TreEat study at AAAAI 2026.

Multi-Nut OFC Feasible, Comparable to Home Introduction in Infants With Peanut Allergy, With Vicki McWilliam, MND, PhD

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

Immunomodulation for Plant-Based Food Allergy, With María José Torres Jaén, MD, PhD

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.